Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront

MT Newswires Live

2024/11/27

Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.

Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.

Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.

Price: 16.06, Change: -0.15, Percent Change: -0.93

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2486783078"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2486783078\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2486783078?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-27 06:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2486783078","market":"nz","top_or_hot":-1,"title":"Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront","media":"MT Newswires Live","content":"<html><body><p> Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.</p><p>Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.</p><p>Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.</p><p>Price: 16.06, Change: -0.15, Percent Change: -0.93</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcadia Pharmaceuticals Licenses Saniona's SAN711 for $28 Million Upfront\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-27 06:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.</p><p>Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.</p><p>Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.</p><p>Price: 16.06, Change: -0.15, Percent Change: -0.93</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2486783078","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2486783078","pubTimestamp":1732658892,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Acadia Pharmaceuticals  said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.Price: 16.06, Change: -0.15, Percent Change: -0.93","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","AKR":"阿卡迪亚房地产信托","BK4231":"零售房地产信托","BK4080":"零售业房地产投资信托","ACAD":"阿卡迪亚","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC"},"translate_title":"Acadia Pharmaceuticals预付2800万美元授权Saniona的SAN711","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKR":1,"ACAD":0.9},"content_text":"Acadia Pharmaceuticals (ACAD) said Tuesday it will pay Saniona $28 million as part of an exclusive worldwide license agreement for the development and commercialization of SAN711 to treat rare neuropathic disorders and absence seizures.Under the agreement, Acadia will also pay Saniona up to $582 million in milestone payments as well as tiered royalties.Acadia said it will lead the development, regulatory and commercialization efforts of SAN711 and provide support for additional studies.Price: 16.06, Change: -0.15, Percent Change: -0.93","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}